Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
61.31
+0.73 (1.21%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Royalty Pharma Revenue
Royalty Pharma had revenue of $674.14M in the quarter ending June 30, 2026, with 16.50% growth. This brings the company's revenue in the last twelve months to $2.54B, up 10.01% year-over-year. In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth.
Revenue (ttm)
$2.54B
Revenue Growth
+10.01%
P/S Ratio
13.90
Revenue / Employee
$25,359,980
Employees
100
Market Cap
35.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.62M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Moderna | 2.23B |
| Ascendis Pharma | 1.20B |
RPRX News
- 6 days ago - Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma - TheFly
- 10 days ago - Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million - GlobeNewsWire
- 10 days ago - Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide - GlobeNewsWire
- 11 days ago - Royalty Pharma Slides: Corporate presentation - Filings
- 16 days ago - Royalty Pharma price target raised to $66 from $59 at Goldman Sachs - TheFly
- 16 days ago - Royalty Pharma price target raised to $65 from $64 at Morgan Stanley - TheFly
- 16 days ago - Royalty Pharma price target raised to $70 from $66 at Citi - TheFly
- 17 days ago - Royalty Pharma Earnings Call Transcript: Q2 2026 - Transcripts